Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31,954 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.
Bian D, Sun L, Hu J, Duan L, Xia H, Zhu X, Sun F, Zhang L, Yu H, Xiong Y, Huang Z, Zhao D, Song N, Yang J, Bao X, Wu W, Huang J, He W, Zhu Y, Jiang G, Zhang P. Bian D, et al. Among authors: sun l, sun f. Nat Commun. 2023 Aug 3;14(1):4655. doi: 10.1038/s41467-023-40349-z. Nat Commun. 2023. PMID: 37537219 Free PMC article. Clinical Trial.
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H, Hou L, Wu C, Zhu Y, Jiang G, Zhu H, Zhou Y, Fang S, Zhang T, Hu L, Li J, Liu Y, Zhang H, Zhang B, Ding L, Robles AI, Rodriguez H, Gao D, Ji H, Zhou H, Zhang P. Liu Q, et al. Among authors: sun l. Cell. 2024 Jan 4;187(1):184-203.e28. doi: 10.1016/j.cell.2023.12.004. Cell. 2024. PMID: 38181741
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
Xia H, Zhang H, Ruan Z, Zhang H, Sun L, Chen H, Zhou Y, Zhang L, Bian D, Zhu X, Zhang J, Sun F, Yu H, Song N, Liu X, Zhu Y, Zhang H, He W, Chen J, Yang J, Chen G, Xie S, Tang D, Zhang X, Duan L, Zhao D, Li Q, Zhang P, Jiang G. Xia H, et al. Among authors: sun l, sun f. Signal Transduct Target Ther. 2024 Jun 14;9(1):145. doi: 10.1038/s41392-024-01861-w. Signal Transduct Target Ther. 2024. PMID: 38871690 Free PMC article. Clinical Trial.
Comprehensive genomic profiling of combined small cell lung cancer.
Zhang J, Zhang L, Luo J, Ge T, Fan P, Sun L, Hou L, Li J, Yu H, Wu C, Zhu Y, Wu C, Jiang G, Troncone G, Malhotra J, Okuda K, Santarpia M, Zamarchi R, Goto T, Cardona AF, Xu J, Chen Q, Zhang Z, Zhang P; written on behalf of the AME Lung Cancer Collaborative Group. Zhang J, et al. Among authors: sun l. Transl Lung Cancer Res. 2021 Feb;10(2):636-650. doi: 10.21037/tlcr-20-1099. Transl Lung Cancer Res. 2021. PMID: 33718010 Free PMC article.
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X, Sun L, Song N, He W, Xie B, Hu J, Zhang J, Yang J, Dai J, Bian D, Xia H, Sun F, Xiong A, Luo J, Zhang L, Yu H, Liu M, Liu H, Wang H, Zhang H, Chen C, Wu C, Duan L, Zhu Y, Zhang P, Jiang G. Zhu X, et al. Among authors: sun l, sun f. BMC Med. 2022 Dec 30;20(1):493. doi: 10.1186/s12916-022-02696-4. BMC Med. 2022. PMID: 36581917 Free PMC article. Clinical Trial.
31,954 results
You have reached the last available page of results. Please see the User Guide for more information.